Monocyclic compound

Patent metadata

Field	Value
Publication number	US-10252997-B2
Application number	US-201615563128-A
Country	US
Kind code	B2
Filing date	Mar 30, 2016
Priority date	Mar 31, 2015
Publication date	Apr 9, 2019
Grant date	Apr 9, 2019

Abstract

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

First claim

The invention claimed is:

1. A compound represented by the formula (I):

wherein
R 1 is a C 1-6 alkyl group or an amino group;
R 2 is a C 1-6 alkyl group;
X is —C(R 3 )(R 4 )—, or —O—;
R 3 and R 4 are each independently a hydrogen atom or a hydroxy group;
Ring Q is benzene, a 6-membered monocyclic aromatic heterocycle or a 6-membered monocyclic non-aromatic heterocycle, each optionally substituted by 1 to 3 substituents selected from (a) a halogen atom, (b) a cyano group and (c) a C 1-6 alkyl group;
Ring R is benzene, a 5- or 6-membered monocyclic aromatic heterocycle or a 5- or 6-membered monocyclic non-aromatic heterocycle, each optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) an oxo group,
(c) a C 1-6 alkyl group, and
(d) a C 1-6 alkoxy group optionally substituted by 1 to 3 substituents selected from (i) a halogen atom and (ii) a C 3-10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms:

Ring S is a 5-membered monocyclic aromatic heterocycle or a 5-membered monocyclic non-aromatic heterocycle, each optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) an optionally halogenated C 1-6 alkyl group, and

(c) a C 1-6 alkoxy group;
p is 1; and
q is 0,
or a salt thereof.

2. The compound or salt according to claim 1 , wherein X is —O—.

3. N((-2S)-1-((2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-oxazol-5-yl)oxy)propan-2-yl)acetamide or a salt thereof.

4. 1-((2S)-1-((2-(4-(3-(Cyclopropylmethoxy)phenoxy)phenyl)-1,3-oxazol-5-yl)oxy)propan-2-yl)urea or a salt thereof.

5. A pharmaceutical composition comprising the compound or salt according to claim 1 , and a pharmaceutically acceptable carrier.

6. A method for treatment of hepatitis, hepatic fibrosis or fatty liver in a mammal, which comprises administering an effective amount of the compound or salt according to claim 1 to the mammal.

Assignees

• Takeda Pharmaceuticals Co

Inventors

• Mizojiri Ryo
• Asano Moriteru
• Tomita Daisuke
• Banno Hiroshi
• Tawada Michiko
• Nii Noriyuki
• Gipson Krista E
• Maezaki Hironobu
• Tsuchiya Shuntarou
• Imai Mayumi
• Amano Yuichiro

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D213/69

  Two or more oxygen atoms · CPC title

• A61K31/50

  Pyridazines; Hydrogenated pyridazines · CPC title

• C07D207/12

  Oxygen or sulfur atoms · CPC title